Vasculitis is a group of disorders defined by inflammation of blood-vessel walls. It can affect arteries, arterioles, capillaries, venules, or veins, ranging from microscopic vessels in the skin to the aorta and its major branches. Inflammation may narrow or obstruct a vessel, weaken its wall, or increase its permeability, producing tissue ischemia, bleeding, or an aneurysm. Some forms remain confined to one organ; others involve several organ systems and can become life-threatening.
Vasculitis is not a single disease with one cause or treatment. Its different forms have distinct age distributions, tissue patterns, immune mechanisms, and associations with infections, medications, and other diseases. Classification relies principally on the predominant size of affected vessels and on characteristic pathological or immunological findings. Clinical assessment combines the pattern of organ involvement with laboratory tests, imaging, and, where appropriate, tissue examination. Modern treatment has substantially improved outcomes in several severe forms, although relapse, irreversible organ injury, and treatment toxicity remain important problems.
Definition, nomenclature, and classification
The defining lesion of vasculitis is inflammation within a blood-vessel wall, usually accompanied by structural injury. Inflammatory cells merely surrounding a vessel do not necessarily establish vasculitis: similar changes occur in infections, inflammatory skin disorders, and other conditions. Conversely, a previously inflamed vessel may show scarring or narrowing after active inflammation has subsided. These distinctions connect the clinical diagnosis with pathology while explaining why neither symptoms nor a single tissue feature can classify every case.
The 2012 revised International Chapel Hill Consensus Conference nomenclature organizes vasculitis primarily by the size of vessels predominantly involved. Large-vessel vasculitis mainly affects the aorta and its major branches. Medium-vessel vasculitis predominantly affects the main visceral arteries and their branches. Small-vessel vasculitis affects intraparenchymal arteries, arterioles, capillaries, and venules. These categories overlap: a disease classified as small-vessel vasculitis may also involve medium-sized arteries, and large-vessel disease may extend into smaller branches.
Small-vessel vasculitis is further divided into antineutrophil cytoplasmic antibody-associated disease and immune-complex disease. The former includes granulomatosis with polyangiitis, microscopic polyangiitis, and eosinophilic granulomatosis with polyangiitis. The latter includes IgA vasculitis, cryoglobulinemic vasculitis, and hypocomplementemic urticarial vasculitis. Anti-glomerular basement membrane disease is also included within the Chapel Hill immune-complex small-vessel category, although its characteristic antibody deposits form a linear rather than granular pattern.
Other categories address diseases that do not fit a simple vessel-size hierarchy. Variable-vessel vasculitis, exemplified by Behçet disease, can affect arteries and veins of different sizes. Single-organ vasculitis describes disease restricted to one organ without evidence that it represents a limited expression of a systemic vasculitis. Additional categories identify vasculitis associated with systemic diseases, such as rheumatoid arthritis, or with a probable cause, such as hepatitis C infection or a medication.
Nomenclature, classification criteria, and diagnostic criteria serve different purposes. Nomenclature supplies names and definitions. Classification criteria create relatively homogeneous groups for research, generally after vasculitis has been established and mimicking disorders excluded. The 2022 American College of Rheumatology/European Alliance of Associations for Rheumatology criteria use weighted clinical, laboratory, imaging, and pathological features for several major vasculitides. They are not screening rules for unexplained symptoms and do not replace a clinical diagnosis.
Epidemiology and associated causes
The epidemiology of vasculitis varies markedly by disease, age, ancestry, geography, and method of case ascertainment. Combining all vasculitides into one frequency estimate conceals clinically important differences. Giant cell arteritis is predominantly a disease of people older than 50 years and is particularly frequent in populations of northern European ancestry. IgA vasculitis and Kawasaki disease are important childhood vasculitides, whereas antineutrophil cytoplasmic antibody-associated vasculitis is most often diagnosed in middle-aged or older adults, although it can occur at other ages.
Published estimates for giant cell arteritis in people aged 50 years or older range from fewer than 1 to more than 20 new cases per 100,000 people annually across different populations. Combined annual estimates for the major antineutrophil cytoplasmic antibody-associated vasculitides in many European populations are roughly 10–30 per million. These are approximate ranges rather than universal rates. Apparent increases over time may reflect population aging, improved recognition, wider antibody testing, and changes in classification as well as changes in disease occurrence.
Genetic susceptibility contributes to several forms without usually determining disease on its own. HLA associations are prominent in giant cell arteritis, Takayasu arteritis, and Behçet disease. In antineutrophil cytoplasmic antibody-associated vasculitis, genetic associations differ between disease associated with proteinase 3 antibodies and disease associated with myeloperoxidase antibodies. This finding suggests that antibody specificity captures biological differences not fully represented by traditional clinical labels.
Some vasculitides have identifiable infectious associations. Hepatitis B can cause a subset of polyarteritis nodosa, and hepatitis C is strongly associated with mixed cryoglobulinemic vasculitis. Widespread hepatitis B vaccination and control of viral transmission have changed the frequency of hepatitis B-associated disease in many settings. Infections can also mimic primary vasculitis: infective endocarditis, for example, may produce purpura, kidney inflammation, and occasionally positive antineutrophil cytoplasmic antibodies.
Medications and exposures provide another group of associations. Hydralazine and propylthiouracil can cause antineutrophil cytoplasmic antibody-associated syndromes. Levamisole-adulterated cocaine has been linked to characteristic skin injury and autoimmune laboratory findings. Other medications can provoke cutaneous small-vessel vasculitis. A temporal association alone does not establish causation, because infection, the illness being treated, and coincidental autoimmune disease may provide alternative explanations.
Most primary vasculitides have no single established initiating cause. Proposed environmental contributors include inhaled silica and microbial exposures, but their evidential strength differs between diseases. Vasculitis is therefore best understood as a collection of disorders arising through different combinations of genetic susceptibility, immune dysregulation, environmental exposure, and, in some cases, a recognizable secondary cause.
Mechanisms of vascular injury
The immune system damages vessels through several distinct pathways. The vessel wall is not merely a passive target: endothelial cells, vascular smooth-muscle cells, resident immune cells, and surrounding connective tissue participate in inflammatory signaling and repair. Injury may be segmental rather than continuous, and different stages of inflammation and scarring may coexist. This patchiness helps explain why a tissue sample can be negative despite disease elsewhere in the same vascular territory.
In antineutrophil cytoplasmic antibody-associated vasculitis, antibodies commonly recognize proteinase 3 or myeloperoxidase, proteins associated with neutrophil granules. Inflammatory priming makes these targets more accessible at the neutrophil surface. Antibody binding promotes neutrophil activation, adhesion to endothelium, release of damaging enzymes and reactive oxygen species, and formation of extracellular traps. These processes injure small vessels and amplify inflammation.
The complement system reinforces this response, particularly through the alternative pathway and the inflammatory mediator C5a. C5a recruits and primes additional neutrophils, creating an amplification loop. This mechanism is supported by experimental models and by the clinical efficacy of C5a-receptor blockade in selected patients. The term pauci-immune describes the relative scarcity of immunoglobulin deposits in affected tissue; it does not mean that antibodies or complement have no pathogenic role.
Immune-complex vasculitis follows a different pattern. Antigen–antibody complexes accumulate in vessel walls, activate complement, and recruit inflammatory cells. In IgA vasculitis, abnormalities involving IgA1 and antibodies directed against it contribute to IgA-containing deposits, particularly in skin and kidney tissue. In cryoglobulinemic disease, circulating immunoglobulins that precipitate at low temperatures can participate in vascular inflammation. These mechanisms explain why direct immunofluorescence and complement measurements can help distinguish disease groups.
Large-vessel vasculitis is characterized more by cellular immune responses within arterial walls. Activated dendritic cells, T cells, and macrophages participate in granulomatous inflammation. Cytokines including interleukin-6 and interferon-gamma contribute to inflammatory recruitment and tissue remodeling. Thickening of the intima can obstruct blood flow, while destruction of elastic and muscular structures can weaken the vessel and permit dilation.
The final consequences depend on the vessel and tissue involved. Leakage from superficial dermal vessels produces purpura; disruption of pulmonary capillaries can cause alveolar hemorrhage. Arterial narrowing or thrombosis reduces downstream perfusion, whereas wall destruction can cause rupture or aneurysm formation. Repair can leave fixed stenosis or fibrosis even after immune activity has been controlled. Active inflammation and accumulated structural damage are therefore related but distinct components of vasculitic disease.
Large- and medium-vessel vasculitides
Giant cell arteritis affects large and medium arteries, particularly branches of the external carotid artery and, in many patients, the aorta and its branches. Cranial manifestations include a new headache, scalp tenderness, and jaw claudication, meaning pain or fatigue of the jaw muscles during chewing. Involvement of arteries supplying the optic nerve can cause ischemic visual loss. The disease frequently overlaps with polymyalgia rheumatica, which produces inflammatory pain and stiffness around the shoulders and hips.
The name refers to multinucleated giant cells that may be present in inflamed arterial tissue, but their absence does not exclude the disease. Inflammation is often discontinuous, producing “skip lesions” in temporal artery specimens. Some patients have predominantly extracranial disease, with constitutional symptoms, arm claudication, unequal pulses, or imaging abnormalities of the aorta. Aortic dilation and aneurysm may become apparent later, including after the initial inflammatory episode.
Takayasu arteritis also affects the aorta and its major branches but usually begins earlier in life. It can involve the subclavian, carotid, renal, mesenteric, and pulmonary arteries. Progressive narrowing may cause diminished pulses, blood-pressure differences between limbs, bruits, or limb claudication. Renal artery disease can produce hypertension, while aortic root involvement can contribute to aortic valve regurgitation. Imaging is central because affected vessels are generally inaccessible to routine biopsy.
Polyarteritis nodosa is a necrotizing arteritis of medium or small arteries that, by definition, does not cause glomerulonephritis or vasculitis of capillaries, venules, and arterioles. Renal arterial lesions can cause ischemia and hypertension, but inflammation of the kidney filtration units suggests another diagnosis. Abdominal pain, skin nodules, livedo, muscle pain, and asymmetric peripheral nerve injury are characteristic presentations. Angiography may reveal arterial stenoses and small aneurysms, particularly in renal or mesenteric branches. Hepatitis B-associated disease represents a distinct etiological subset.
Kawasaki disease is an acute childhood vasculitis with a particular tendency to involve the coronary arteries. Its clinical pattern includes persistent fever, conjunctival redness, oral changes, rash, extremity changes, and cervical lymph-node enlargement, although incomplete presentations occur. Coronary artery dilation or aneurysm is the principal vascular complication. Intravenous immunoglobulin, introduced into standard treatment during the 1980s, substantially reduced the frequency of coronary complications.
These conditions illustrate why vessel size alone is insufficient for clinical interpretation. Age, vascular distribution, tissue pathology, and associated manifestations distinguish diseases with overlapping anatomical targets. Their complications also differ: visual ischemia is a defining concern in cranial giant cell arteritis, renovascular hypertension is important in Takayasu arteritis and polyarteritis nodosa, and coronary injury dominates long-term assessment after Kawasaki disease.
Small- and variable-vessel vasculitides
Antineutrophil cytoplasmic antibody-associated vasculitis, commonly abbreviated AAV, comprises three major syndromes. Granulomatosis with polyangiitis combines necrotizing granulomatous inflammation, often involving the respiratory tract, with small- to medium-vessel vasculitis. Chronic sinus disease, otitis, nasal injury, pulmonary nodules, and glomerulonephritis are characteristic, although no individual patient must have every feature. Proteinase 3 antibodies are common, but antibody-negative and myeloperoxidase-positive cases also occur.
Microscopic polyangiitis causes necrotizing small-vessel vasculitis without the granulomatous respiratory inflammation characteristic of granulomatosis with polyangiitis. Kidney disease and pulmonary capillaritis are major manifestations. Myeloperoxidase antibodies are frequent, and some patients also have interstitial lung disease. The clinical distinction between microscopic polyangiitis and granulomatosis with polyangiitis remains useful, but antibody specificity can add information about genetics, relapse patterns, and phenotype.
Eosinophilic granulomatosis with polyangiitis is associated with asthma, blood and tissue eosinophilia, and eosinophil-rich inflammation. Manifestations include chronic sinonasal disease, pulmonary infiltrates, peripheral nerve injury, skin disease, and cardiac involvement. Only a minority of patients have detectable antineutrophil cytoplasmic antibodies, usually against myeloperoxidase. Antibody-positive disease more often includes glomerulonephritis and certain vasculitic manifestations, whereas eosinophilic tissue and cardiac disease are prominent in many antibody-negative cases; these are tendencies rather than absolute divisions.
IgA vasculitis typically produces non-blanching palpable purpura, especially on the legs, together with variable joint symptoms, abdominal involvement, and kidney disease. It is commonest in children, but adults can develop substantial renal complications. Cryoglobulinemic disease can cause purpura, arthralgia, neuropathy, and glomerulonephritis. Its evaluation includes consideration of hepatitis C infection, autoimmune disease, and B-cell disorders. Cutaneous leukocytoclastic angiitis describes a skin-limited small-vessel inflammatory pattern after systemic involvement and specific causes have been assessed.
Behçet disease belongs to the variable-vessel group because it can affect arteries and veins of any size. Recurrent oral ulcers, genital ulcers, ocular inflammation, skin lesions, and vascular or neurological involvement form its clinical spectrum. Venous thrombosis is common among its vascular manifestations, and pulmonary artery aneurysms are a distinctive severe complication. Vascular inflammation contributes directly to thrombosis, making the disease different from a simple inherited or acquired clotting tendency.
Not all diseases with pulmonary hemorrhage and kidney inflammation are AAV. Anti-glomerular basement membrane disease results from antibodies directed against basement-membrane components and has a characteristic linear staining pattern in kidney tissue. Distinguishing it from pauci-immune vasculitis and immune-complex disease matters because their mechanisms, associated findings, and treatment strategies differ.
Organ manifestations and clinical patterns
Vasculitis may begin with systemic symptoms such as fever, weight loss, night sweats, muscle aches, and fatigue. These reflect inflammation but are not specific to vascular disease. Some patients instead present with a dominant organ problem, such as a rash, sudden visual impairment, kidney dysfunction, or a focal nerve deficit. The diagnostic significance lies in the combination of manifestations, their timing, and the vascular territories involved.
Skin findings are particularly visible but vary with vessel depth and size. Small-vessel inflammation commonly causes palpable purpura: raised, non-blanching lesions produced by blood escaping into the skin. Larger-vessel involvement can produce nodules, ulcers, digital ischemia, or branching, netlike areas of discoloration. Similar appearances can arise from non-inflammatory vessel occlusion, so visual inspection alone cannot establish vasculitis. Lesion age and depth influence the usefulness of a skin biopsy.
Kidney involvement may initially cause few symptoms. Blood and protein in urine can precede a marked rise in serum creatinine. In necrotizing glomerulonephritis, inflammatory destruction of glomerular capillary walls may lead to rapidly progressive loss of filtration. Crescent formation on biopsy reflects a severe response to glomerular injury. By contrast, renal arterial vasculitis may primarily produce ischemia or hypertension rather than an inflammatory urine sediment.
Pulmonary involvement includes nodules, cavities, interstitial abnormalities, and diffuse alveolar hemorrhage. Alveolar hemorrhage can produce breathlessness, falling hemoglobin, and diffuse lung opacities; coughing blood is not invariably present. Infection, pulmonary edema, and other causes of lung injury may look similar. A pulmonary–renal syndrome denotes the combination of pulmonary hemorrhage and glomerulonephritis, not a single etiological diagnosis.
Inflammation of vessels supplying peripheral nerves can produce mononeuritis multiplex, an asymmetric pattern affecting separate nerves. Pain, sensory loss, foot drop, or wrist drop may appear sequentially. Central nervous system involvement is less common in many systemic vasculitides but can cause stroke, seizures, or cognitive changes. Primary angiitis of the central nervous system is a separate, uncommon disorder with a broad range of mimics.
Other manifestations include intestinal ischemia, abdominal bleeding, ocular inflammation, hearing impairment, and cardiac disease. Abdominal pain can arise from mesenteric arterial involvement or small-vessel injury within the bowel. Eye disease may result from ischemia or direct inflammatory involvement of ocular tissues. The clinical importance of these manifestations depends not only on how widespread inflammation is, but also on how much irreversible damage can occur in the affected tissue.
Diagnostic investigation and exclusion of mimics
Investigation begins by establishing whether the clinical pattern plausibly reflects vascular inflammation and whether organ-threatening disease is present. A detailed medical history addresses symptom evolution, medications, substance exposure, infections, and associated inflammatory disorders. Examination includes skin and neurological findings, pulses, blood pressure in relevant limbs, vascular bruits, and signs of ocular, respiratory, or cardiac disease. No single investigation reliably confirms or excludes every form of vasculitis.
Initial laboratory assessment commonly includes a complete blood count, kidney and liver measurements, inflammatory markers, and urinalysis. Urine microscopy can identify dysmorphic red cells or red-cell casts supporting glomerular injury. Erythrocyte sedimentation rate and C-reactive protein are useful indicators of inflammation but lack specificity. They can be normal in some active disease and can rise because of infection or another inflammatory process.
Antineutrophil cytoplasmic antibody testing is most informative when the clinical presentation suggests AAV. Antigen-specific assays identify antibodies to proteinase 3 and myeloperoxidase. A positive result is not equivalent to a diagnosis: antibodies may occur with infections, medication reactions, and other inflammatory conditions. A negative result does not exclude limited granulomatosis with polyangiitis, eosinophilic granulomatosis with polyangiitis, or other vasculitides. Complement levels, cryoglobulins, hepatitis testing, and anti-glomerular basement membrane antibodies address different diagnostic possibilities.
Biopsy can demonstrate vessel-wall inflammation, necrosis, granulomas, or characteristic immune deposits. The appropriate tissue depends on the clinical distribution and the balance between likely diagnostic yield and procedural risk. Kidney biopsy often provides both diagnostic and prognostic information. Skin biopsy can distinguish inflammatory from occlusive processes and permit direct immunofluorescence. Temporal artery biopsy supports giant cell arteritis, but segmental disease can produce false-negative specimens.
Imaging is especially important in large- and medium-vessel disease. Ultrasonography can demonstrate arterial wall thickening, including the halo sign in suitable vascular territories. Magnetic resonance imaging and angiography can assess wall abnormalities and vessel anatomy, while computed tomography angiography depicts stenoses, aneurysms, and other structural changes. Positron emission tomography can identify increased metabolic activity in inflamed large-vessel walls, although uptake is not specific and interpretation is affected by treatment and other vascular disease.
The differential diagnosis includes infection, atherosclerosis, embolic disease, cholesterol crystal embolization, thrombotic microangiopathy, and non-inflammatory arteriopathies. Reversible cerebral vasoconstriction syndrome can mimic central nervous system vasculitis on angiography. Malignancy and systemic autoimmune diseases can produce overlapping constitutional, cutaneous, or renal findings. Diagnostic confidence therefore rests on converging clinical, laboratory, imaging, and pathological evidence rather than an isolated positive test.
Treatment principles and disease-specific therapies
Treatment depends on the particular vasculitis, the organs involved, current disease activity, and the likelihood of irreversible injury. A central distinction is between inducing remission in active disease and maintaining remission after control has been achieved. Another is between treatment of inflammation and management of established damage. A scarred artery, damaged nerve, or chronically impaired kidney may remain abnormal even when additional immunosuppression would provide little benefit.
Glucocorticoids have a rapid anti-inflammatory effect and remain important in many systemic vasculitides. Their cumulative toxicity—including infection, diabetes, osteoporosis, cataracts, and cardiovascular effects—has driven efforts to reduce exposure. Severe granulomatosis with polyangiitis and microscopic polyangiitis are commonly treated with glucocorticoids plus rituximab or cyclophosphamide. Rituximab depletes CD20-positive B cells, whereas cyclophosphamide suppresses proliferating immune cells more broadly. Less organ-threatening disease and maintenance treatment involve different regimens.
Clinical trials have refined these approaches. The 2010 RAVE trial established rituximab as an effective alternative to cyclophosphamide-based induction for severe AAV, with particular efficacy in relapsing disease. MAINRITSAN trials supported rituximab-based maintenance strategies. The 2020 PEXIVAS trial found that routine plasma exchange did not significantly reduce the combined risk of death or end-stage kidney disease in its study population with severe AAV; it also supported a reduced-dose glucocorticoid regimen. These findings did not eliminate the need to consider distinct indications for plasma exchange, particularly anti-glomerular basement membrane disease.
Targeted therapies address specific inflammatory pathways. Avacopan blocks the C5a receptor and has been studied as part of treatment for granulomatosis with polyangiitis and microscopic polyangiitis. In giant cell arteritis, the interleukin-6 receptor inhibitor tocilizumab increased sustained glucocorticoid-free remission in the 2017 GiACTA trial. Mepolizumab, which targets interleukin-5, has evidence in relapsing or refractory eosinophilic granulomatosis with polyangiitis. These agents do not have interchangeable roles across all vasculitides.
Secondary vasculitis may require treatment of its underlying driver. Direct-acting antiviral therapy transformed management of hepatitis C-associated cryoglobulinemic disease, although severe organ involvement may also require immune-directed treatment. Hepatitis B-associated polyarteritis nodosa has a different therapeutic rationale from nonviral disease. Withdrawal of an implicated medication is central in drug-induced disease, while infection-associated vascular injury requires antimicrobial treatment rather than indiscriminate immunosuppression.
Supportive care addresses organ injury and treatment complications. It can include blood-pressure control, infection prevention, bone protection, rehabilitation, and kidney replacement therapy. Surgery or endovascular procedures may be needed for selected aneurysms, critical stenoses, or other structural complications. Their timing depends partly on inflammatory activity, because intervention in an actively inflamed vessel can carry different risks from intervention in stable residual disease.
Disease course, monitoring, and long-term outcomes
The course of vasculitis ranges from a single self-limited episode to chronic relapsing disease. Some skin-limited episodes resolve after an infection subsides or an implicated medication is withdrawn. Systemic AAV, giant cell arteritis, Takayasu arteritis, and Behçet disease often require prolonged observation because activity can recur or structural complications can evolve. Remission means absence of active disease according to a defined clinical assessment; it does not necessarily mean that symptoms, treatment, or previous organ damage have disappeared.
Relapse risk differs across and within disease categories. Proteinase 3-associated AAV generally has a greater tendency to relapse than myeloperoxidase-associated disease, although individual courses vary. Previous relapse, respiratory involvement, and treatment history can also influence risk. A rising antibody concentration may contribute to assessment but does not consistently predict when or where relapse will occur. Treatment decisions based solely on antibody levels can therefore misclassify patients.
Monitoring separates active inflammation from fixed damage and unrelated illness. Persistent blood in urine may reflect ongoing glomerular inflammation, but it may also remain after substantial injury has healed. Breathlessness may result from active pulmonary disease, chronic scarring, infection, anemia, or cardiac dysfunction. Serial clinical assessment, urine studies, kidney function, and appropriately selected imaging provide complementary information. The Birmingham Vasculitis Activity Score measures disease activity, whereas the Vasculitis Damage Index records persistent damage rather than current inflammation.
Long-term outcomes are shaped by both disease and treatment. Severe kidney injury can progress to chronic kidney disease or require dialysis. Peripheral nerve injury may recover incompletely. Large-vessel disease can leave aneurysms or stenoses that remain clinically important after inflammatory markers normalize. Infection is a major source of illness during intensive immunosuppression, while cumulative glucocorticoid exposure and some other therapies contribute additional metabolic, skeletal, reproductive, or malignant complications.
Survival in severe AAV improved markedly after glucocorticoids and cyclophosphamide became established treatments, and later developments expanded the options for disease control. Nevertheless, prognosis cannot be represented by one survival figure for all vasculitis. Age, initial kidney function, pulmonary hemorrhage, cardiac involvement, infection, and accumulated damage have different importance in different diseases. In eosinophilic granulomatosis with polyangiitis, for example, cardiac involvement is a particularly important determinant of adverse outcome.
Health-related quality of life may remain impaired even during clinical remission. Fatigue, pain, sensory deficits, reduced exercise capacity, and difficulty returning to work are not fully captured by vascular imaging or laboratory markers. Patient-reported outcomes therefore complement activity and damage indices, distinguishing control of inflammation from restoration of everyday functioning.
Historical development and continuing research
Early descriptions of vasculitis emerged from clinical observation and postmortem pathology rather than immunology. In 1866, Adolf Kussmaul and Rudolf Maier described the disorder later known as polyarteritis nodosa, linking systemic illness with nodular arterial lesions. Subsequent work separated several conditions that had previously been grouped under broad terms such as periarteritis or hypersensitivity angiitis. The increasing ability to examine small vessels and kidney tissue was crucial to recognizing distinct pathological patterns.
The twentieth century brought clearer descriptions of granulomatous respiratory and renal disease, eosinophilic vasculitis, and childhood coronary arteritis. Jacob Churg and Lotte Strauss described allergic granulomatosis and angiitis in 1951, the condition now termed eosinophilic granulomatosis with polyangiitis. Tomisaku Kawasaki reported the childhood syndrome bearing his name in 1967. Disease names have continued to change as nomenclature increasingly emphasizes pathological features rather than eponyms.
A major immunological advance occurred in 1982 when antibodies against neutrophils were reported in patients with necrotizing glomerulonephritis. In 1985, a strong association between antineutrophil cytoplasmic antibodies and the disease now called granulomatosis with polyangiitis was demonstrated. Identification of proteinase 3 and myeloperoxidase as principal targets subsequently connected laboratory findings with cellular mechanisms. The 1994 and 2012 Chapel Hill nomenclature conferences helped standardize terminology across clinical studies and specialties.
Research now seeks a more biologically precise classification. Traditional disease labels remain useful, but they do not fully capture differences among antibody specificity, genetic susceptibility, tissue inflammation, and relapse behavior. Studies of immune-cell populations, gene expression, and circulating proteins examine whether apparently similar clinical syndromes contain distinct mechanistic subgroups. A central difficulty is distinguishing a marker of general inflammation from a marker that specifically identifies vascular injury or predicts a clinically meaningful event.
Imaging research addresses another unresolved problem: whether persistent vessel-wall thickening or metabolic uptake represents continuing inflammation, tissue repair, or established damage. The answer affects assessment of remission and interpretation of treatment response. Similar uncertainty applies to some laboratory biomarkers, especially when targeted treatment directly suppresses a measured inflammatory pathway. Interleukin-6 blockade, for example, reduces C-reactive protein production and changes the relationship between that measurement and disease activity.
The rarity and heterogeneity of many vasculitides make adequately powered trials difficult. International collaborative networks, standardized outcome measures, and randomized controlled trials have made comparisons possible that were previously impractical. Continuing questions include the optimal duration of maintenance treatment, reliable prediction of relapse, reduction of glucocorticoid exposure, and treatment strategies for patients poorly represented in trials. Children, people with major comorbidity, and patients with uncommon organ manifestations remain particularly important populations for disease-specific investigation.